AI Could Widen the Healthcare Access Gap. It Doesn't Have To.

I have sat in enough rooms with global health technology vendors to notice a pattern that gets less attention than it deserves: the overwhelming majority of clinical AI development happens against data, infrastructure, and budgets that exist in a fairly narrow slice of the world's health systems. The models get trained on data from large academic medical centers with well-maintained electronic records, the pilots get run in health systems that already have strong connectivity and IT staff, and the pricing gets set for organizations that can absorb enterprise software costs without blinking. None of that is malicious, it is simply where the resources and the easiest path to a working product happen to be. But the effect, if nobody corrects for it deliberately, is a technology that gets progressively better at serving systems that were already relatively well served, while systems with less infrastructure, less clean data, and tighter budgets are left further behind than they were before AI arrived at all.

I do not think this outcome is inevitable, but I am convinced it is the default outcome, the one you get if you simply let market incentives run without anyone actively steering against them. A vendor optimizing for the fastest path to revenue will always find it easier to sell into a well-resourced system than to do the harder work of building something that functions in a resource-constrained one. Equity in this space is not something that happens on its own. It has to be built in as a design constraint from the start, because it will not be added later once the incentives have already pointed the technology somewhere else.

The specific ways this plays out are worth naming, because they are more mundane than headline-grabbing bias stories and, in my experience, more consequential day to day. A model trained predominantly on one population's clinical data can perform meaningfully worse on patients whose baseline physiology, disease prevalence, or presentation differs from that training population, which is a real risk in health systems serving populations that were underrepresented in the original data. A product designed around assumptions of reliable broadband and a steady supply of devices can simply fail to function in a clinic where connectivity is intermittent and hardware is shared across staff. A workflow designed around a single language and a single regulatory and payer environment can require expensive rebuilding, rather than adaptation, to serve a clinic operating in Arabic, under a different regulatory regime, with a different mix of self-pay and insured patients. Each of these is a solvable engineering and product problem. None of them get solved by accident.

What I have found most persuasive, watching this play out across the GCC and neighboring emerging markets, is that these are not charity problems to be solved after the commercial product is built, they are product requirements that, if taken seriously from day one, tend to produce better and more robust technology even for well-resourced markets. A system built to function on inconsistent connectivity and incomplete records is, almost by construction, a more resilient system everywhere it is deployed.

Closing the gap rather than widening it requires deliberate choices that run against the path of least resistance. It means training and validating models on data that actually reflects the populations a system intends to serve, rather than assuming a model built elsewhere will generalize and finding out the hard way that it does not. It means designing for the infrastructure that exists in a given market rather than the infrastructure a vendor wishes existed, which in practice means building for intermittent connectivity, mixed device quality, and manual data entry alongside more modern integrations, not instead of them. It means pricing and deployment models that make the technology reachable for public health systems and mid-sized regional providers, not only for flagship private hospitals with the largest budgets in a country. And it means genuine local partnership, with regulators, with clinicians who understand the specific patient population, and with the language and cultural context the technology will actually operate in, rather than a headquarters-designed product with a translated interface bolted on at the end.

None of that is a slogan, it is a longer and more expensive way to build, and I understand exactly why many vendors skip it. But I have also seen what happens when it is skipped: technology that works impressively in a demo and then underperforms, or actively misleads, in the setting it was actually deployed into. That gap between demo and deployment is where healthcare AI does the most damage to trust, and trust, once lost in a health system, is extraordinarily hard to rebuild.

This is the reason Hayya Med AI is built in and for the GCC and emerging markets rather than as an afterthought to a Western-first product line. We build with the operating conditions of the region as the starting requirement, not a localization pass at the end: Arabic-first design, workflows that account for the real mix of connectivity and infrastructure across the health systems we work with, and pricing structured so that mid-sized and public providers can adopt the technology, not only the largest private groups. I am not going to claim we have solved equity in healthcare AI, that would be a dishonest claim for any single company to make about a problem this large. What I will say is that we treat it as a design constraint rather than a marketing line, because the alternative, building for the easiest market first and hoping equity happens later, is exactly the pattern that got the industry to where it is today. The gap will not close by accident. It closes because specific companies make specific, harder choices, and we have chosen to be one of them.